secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092265
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Q2 net loss $21.6M; cash $226.1M; OLE interim data Q4; FDA START program
--------------------------------------------------------------------------------

- Net loss $21.6M ($0.34/sh) vs $8.4M loss in Q2 2023; R&D spend $19.7M up from $5.9M on manufacturing.
- Cash, equivalents and marketable securities $226.1M at June 30; projected runway into 2026.
- Open-label extension study all 7 sites activated; interim data planned Q4 2024.
- FDA selected nomlabofusp for START pilot to accelerate development; BLA submission targeted 2H 2025.
- Planning PK run-in study in adolescents by year-end 2024; global confirmatory study by mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024092265/0000950170-24-092265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017024092265/lrmr-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer